Akut lenfoblastik lösemi (ALL) çocukluk çağı kanserleri içinde en sık görülenidir ve tüm çocukluk çağı kanserlerinin %30’unu oluşturur. 1980’lerden bu yana ALL’de sağkalım oranları belirgin şekilde artmış, beş yıllık genel sağkalım oranları %80’nin üzerine çıkmıştır. Sağkalımdaki en büyük başarı standardize edilmiş tedavi protokolleri ile ilişkilidir. Sağkalım oranlarındaki bu başarı oranları ile birlikte hastalığın seyri ve tedavi protokollerinin ağır olması, erken ve geç dönemde tedavi ilişkili ciddi yan etkileri de beraberinde getirmektedir. Bu yan etkilerin çoğu tedavinin ilk bir yılı içinde, indüksiyon döneminde veya hemen sonrasında ortaya çıkmaktadır. Birçok hastada geç dönemde de kanserin kendisine veya tedavisine bağlı kronik fiziksel ve psikolojik problemler de tespit edilebilmektedir. Bu derlemenin amacı ALL tedavisine bağlı erken ve geç dönemde ortaya çıkabilecek yan etkilerin gözden geçirilmesidir.
Acute lymphoblastic leukemia (ALL) is the most common form of cancer in children, comprising approximately 30 percent of all childhood malignancies. Survival rates for ALL have improved dramatically since the 1980s, with current fi ve-year overall survival rates estimated at greater than 80 percent. This improvement in survival is due to treatment of a large number of children on sequential standardized research protocols. While the vast majority of children with ALL enjoy long-term survival/cure, the serious nature of the disease, as well as the aggressiveness of the treatment protocols have resulted in signifi cant early and late treatment-related mortality. Much of the treatment-related mortality occurs during the fi rst year of ALL treatment, often during induction or shortly thereafter. Many long-term survivors of childhood cancer will also develop chronic physical or psychosocial problems as a result of their cancer or its therapy. The purpose of this paper is to review the early and late effects of ALL therapy
Other ID | JA44AE52GY |
---|---|
Journal Section | Collection |
Authors | |
Publication Date | December 1, 2014 |
Submission Date | December 1, 2014 |
Published in Issue | Year 2014 Volume: 8 Issue: 1 |
The publication language of Turkish Journal of Pediatric Disease is English.
Manuscripts submitted to the Turkish Journal of Pediatric Disease will go through a double-blind peer-review process. Each submission will be reviewed by at least two external, independent peer reviewers who are experts in the field, in order to ensure an unbiased evaluation process. The editorial board will invite an external and independent editor to manage the evaluation processes of manuscripts submitted by editors or by the editorial board members of the journal. The Editor in Chief is the final authority in the decision-making process for all submissions. Articles accepted for publication in the Turkish Journal of Pediatrics are put in the order of publication taking into account the acceptance dates. If the articles sent to the reviewers for evaluation are assessed as a senior for publication by the reviewers, the section editor and the editor considering all aspects (originality, high scientific quality and citation potential), it receives publication priority in addition to the articles assigned for the next issue.
The aim of the Turkish Journal of Pediatrics is to publish high-quality original research articles that will contribute to the international literature in the field of general pediatric health and diseases and its sub-branches. It also publishes editorial opinions, letters to the editor, reviews, case reports, book reviews, comments on previously published articles, meeting and conference proceedings, announcements, and biography. In addition to the field of child health and diseases, the journal also includes articles prepared in fields such as surgery, dentistry, public health, nutrition and dietetics, social services, human genetics, basic sciences, psychology, psychiatry, educational sciences, sociology and nursing, provided that they are related to this field. can be published.